"There is Upside to Market Potential and Our Outlook" of SY-1425 - Brookline Capital Markets Bullish on Syros Pharmaceuticals (SYRS) with Buy Rating and $19 Price Target
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $19.00 price target on Syros Pharmaceuticals (NASDAQ: SYRS) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
